Join the Biktarvy group to help and get support from people like you.
Biktarvy News
FDA Approves Biktarvy Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif.--(BUSINESS WIRE) April 26, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data...
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy to Treat People with HIV with Suppressed Viral Loads, Pre-Existing Resistance
FOSTER CITY, Calif.--(BUSINESS WIRE) February 26, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for...
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy for Treatment of HIV-1 in Pediatric Populations
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 18, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new low-dose tablet dosage form of...
FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...
Ask a question
To post your own question to this support group, sign in or create an account.